Arnés Luis, Moreno Paola, Nuche-Berenguer Bernardo, Valverde Isabel, Villanueva-Peñacarrillo Maria L
Department of Metabolism, Nutrition and Hormones, Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040-Madrid, Spain.
Regul Pept. 2009 Feb 25;153(1-3):88-92. doi: 10.1016/j.regpep.2008.08.005. Epub 2008 Sep 5.
Exendin-4, like GLP-1, is insulinotropic, antidiabetic and glucoregulatory among other properties, which are thought to be exerted through the pancreatic GLP-1 receptor; exendin-4 is also an agonist of the GLP-1 stimulatory action upon liver and muscle glucose metabolism, where GLP-1 receptor is distinct from that in the pancreas. We investigated the action of prolonged treatment with exendin-4 upon glucose transport parameters in skeletal muscle and liver of normal rats and streptozotocin-induced type 2 diabetic rats (T2D). Muscle of T2D showed lower than normal glucose transport; exendin-4 did not modify the value in normal but normalized that in the T2D; unlike previously detected with GLP-1, no apparent modification was observed in GLUT-4 expression in either group after exendin-4, except for an increased GLUT-4 protein in normal rats. Yet, exendin-4 significantly stimulated liver GLUT-2-mRNA and -protein in T2D and normal rats, the effect upon GLUT-2-protein in T2D being higher than that in normal animals; this was accompanied by a normalizing action of exendin-4 upon the lower than normal liver glycogen in T2D rats. These data suggest that the liver may represent at least one of the major target organs for exendin-4 to exert its plasma lowering effect in diabetic state.
艾塞那肽-4与胰高血糖素样肽-1(GLP-1)类似,具有促胰岛素分泌、抗糖尿病和调节血糖等特性,这些特性被认为是通过胰腺GLP-1受体发挥作用的;艾塞那肽-4也是GLP-1对肝脏和肌肉葡萄糖代谢刺激作用的激动剂,其中GLP-1受体与胰腺中的不同。我们研究了长期用艾塞那肽-4治疗对正常大鼠和链脲佐菌素诱导的2型糖尿病大鼠(T2D)骨骼肌和肝脏中葡萄糖转运参数的影响。T2D大鼠的肌肉显示出低于正常水平的葡萄糖转运;艾塞那肽-4对正常大鼠的该值没有改变,但使T2D大鼠的该值恢复正常;与先前用GLP-1检测到的不同,艾塞那肽-4处理后两组中葡萄糖转运蛋白4(GLUT-4)的表达均未观察到明显改变,除了正常大鼠中GLUT-4蛋白增加。然而,艾塞那肽-4显著刺激了T2D大鼠和正常大鼠肝脏中的葡萄糖转运蛋白2(GLUT-2)信使核糖核酸(mRNA)和蛋白,对T2D大鼠GLUT-2蛋白的影响高于正常动物;这伴随着艾塞那肽-4对T2D大鼠低于正常水平的肝糖原的正常化作用。这些数据表明,肝脏可能是艾塞那肽-4在糖尿病状态下发挥其降低血糖作用的至少一个主要靶器官。